NEW YORK, Nov. 14, 2016 /PRNewswire/ -- Tonight, on World Diabetes Day, the spire of One World Trade Center will be lit in blue, the official color of diabetes, to raise awareness of the disease.
The lighting results from the collective efforts of The American Diabetes Association®, JDRF, The New York Stem Cell Foundation Research Institute and Novo Nordisk Inc. in collaboration with the Consulate General of Denmark in New York. The organizations are united in the battle against diabetes though prevention, detection, treatment and research.
Nearly 30 million Americans have diabetes and at least another 86 million have prediabetes. Without intervention, as many as 30 percent of those with prediabetes will likely develop type 2 diabetes within five years1. Every 23 seconds, someone in the U.S. is diagnosed with diabetes2.
Blue became the official color of diabetes in 2006 when the International Diabetes Federation developed the blue circle icon to serve as the global symbol for diabetes. The organization selected blue to reflect the color of the sky and of the United Nations' flag.3
About the American Diabetes Association The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.
About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.
About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 140 researchers at leading institutions worldwide, including the NYSCF – Druckenmiller Fellows, the NYSCF – Robertson Investigators, the NYSCF – Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute employs over 45 researchers in New York, and is an acknowledged world leader in stem cell research and in developing pioneering stem cell technologies, including the NYSCF Global Stem Cell ArrayTM. NYSCF focuses on translational research in a model designed to overcome the barriers that slow discovery and replace silos with collaboration. For more information, visit www.nyscf.org
About the Consulate General of Denmark The Consulate General of Denmark in New York is Denmark's official representation in New York. We advise and assist in a number of areas: consular, commercial, investment, cultural and press.
We communicate to the U.S. public on important policy topics with relevance to Denmark, such as green growth, sustainable development and life sciences.
About Novo Nordisk Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.